)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ALTEOGEN
ALTEOGEN (196170) investor relations material
ALTEOGEN Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary11 Aug, 2026
Executive summary
Operates in biopharmaceutical R&D, production, and sales, focusing on proprietary platform technologies for subcutaneous drug delivery and next-generation biologics.
Major revenue from licensing out core technologies (ALT-B4, biosimilars) to global pharma partners, with upfront, milestone, and royalty income.
Recent product launches and regulatory approvals in Korea, China, and Europe for biosimilars and proprietary drugs.
Financial highlights
2026 H1 consolidated revenue: ₩140.5B, down from ₩215.9B in 2025 H1.
Operating income: ₩73.5B (2025 H1: ₩106.9B); net income: ₩101.3B (2025 H1: ₩145.2B).
Gross margin remains strong; basic EPS for H1 2026: ₩1,871.
Cash and cash equivalents at period end: ₩80.4B.
Outlook and guidance
Expects continued stable cash inflow from existing and new licensing deals.
Ongoing expansion of product pipeline and global regulatory submissions for biosimilars and new biologics.
Plans to invest in commercial-scale manufacturing facilities.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ALTEOGEN
- 2024 saw record profits and new global licensing deals, driving strong growth and liquidity.196170
Q4 2024 - H1 2024 net profit hit ₩17.7B, driven by global licensing and milestone payments.196170Q2 2024
- Q3 2024 net income reached ₩8.3B, with strong licensing and R&D-driven growth.196170Q3 2024
- Record Q1 2025 revenue and profit fueled by global licensing, product launches, and strong cash flow.196170Q1 2025
- Record revenue and profit growth fueled by global licensing, robust cash flow, and pipeline expansion.196170Q4 2025
- Record revenue and profit growth in 2025 Q3, fueled by licensing and global product approvals.196170Q3 2025
- H1 2025 revenue and profit soared on licensing deals, with robust cash and pipeline growth.196170Q2 2025
- Q1 2026 delivered high net income and major global licensing deals, supporting future growth.196170Q1 2026
- Strong pipeline, global partnerships, and innovation fuel rapid revenue and product growth.19617044th Annual J.P. Morgan Healthcare Conference Presentation
Next ALTEOGEN earnings date
Q3 202620 Nov, 2026
ALTEOGEN
Next ALTEOGEN earnings date
Q3 202620 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)